The Ultomiris Drug Market is witnessing remarkable growth as healthcare advances bring new hope to patients suffering from rare and life-threatening diseases. Ultomiris (ravulizumab-cwvz), developed by Alexion Pharmaceuticals (a subsidiary of AstraZeneca), is a next-generation complement inhibitor that has redefined the management of diseases such as Paroxysmal Nocturnal...